<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2701256753
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        INFASURF 35 MG/ML INTRATRACHEAL SUSPENSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CALFACTANT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        35
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intratracheal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        892.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="O.N.Y INC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            O.N.Y INC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        NA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Infasurf is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation only.&nbsp; It is an extract of natural surfactant from calf lungs which includes phospholipids, neutral lipids, and hydrophobic surfactant-associated proteins B and C (SP-B and SP-C).</p><p>&nbsp;</p><p>Infasurf is indicated for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment (&ldquo;rescue&rdquo;) of premature infants who develop RDS. Infasurf decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS.</p><p>&nbsp;</p><p><strong>Prophylaxis </strong></p><p>Prophylaxis therapy at birth with Infasurf is indicated for premature infants &lt; 29 weeks of gestational age at significant risk for RDS. Infasurf prophylaxis should be administered as soon as possible, preferably within 30 minutes after birth.</p><p>&nbsp;</p><p><strong>Treatment </strong></p><p>Infasurf therapy is indicated for infants &le; 72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Infasurf</strong></p><ul><li>If you are allergic to calfactant or any of the other ingredients of this medicine (listed in section 6).</li></ul><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p><em>Warnings </em></p><p>Infasurf is intended for intratracheal use only.</p><p>&nbsp;</p><p>The administration of exogenous surfactants, including Infasurf, often rapidly improves oxygenation and lung compliance. Following administration of Infasurf, patients should be carefully monitored so that oxygen therapy and ventilatory support can be modified in response to changes in respiratory status. Infasurf therapy is not a substitute for neonatal intensive care. Optimal care of premature infants at risk for RDS and newborn infants with RDS who need endotracheal intubation requires an acute care unit organized, staffed, equipped, and experienced with intubation, ventilator management, and general care of these patients.</p><p>&nbsp;</p><p>Transient episodes of reflux of Infasurf into the endotracheal tube, cyanosis, bradycardia, or airway obstruction have occurred during the dosing procedures. These events require stopping Infasurf administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing can proceed with appropriate monitoring.</p><p>&nbsp;</p><p><em>Precautions </em></p><p>When repeat dosing was given at fixed 12-hour intervals in the Infasurf vs. colfosceril palmitate trials, transient episodes of cyanosis, bradycardia, reflux of surfactant into the endotracheal tube, and airway obstruction were observed more frequently among infants in the Infasurf-treated group.</p><p>&nbsp;</p><p>An increased proportion of patients with both intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) was observed in Infasurf-treated infants in the Infasurf-colfosceril palmitate-controlled trials. These observations were not associated with increased mortality.</p><p>&nbsp;</p><p>No data are available on the use of infasurf in conjunction with experimental therapies of RDS, e.g., high-frequency ventilation. Data from controlled trials on the efficacy of Infasurf are limited to doses of approximately 100 mg phospholipid/kg body weight and up to a total of 4 doses.</p><p>&nbsp;</p><p><em>Carcinogenesis, mutagenesis, impairment of fertility </em></p><p>Carcinogenesis studies and animal reproduction studies have not been performed with Infasurf. A single mutagenicity study (Ames assay) was negative.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and </strong><strong>Infasurf</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>&nbsp;</p><p><strong>Infasurf</strong><strong> </strong><strong>contains sodium</strong></p><p>Infasurf contains sodium. Each ml of Infasurf 35 mg/ml Intratracheal Suspension contains 3.51 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>For intratracheal administration only.</p><p>&nbsp;</p><p>Infasurf should be administered under the supervision of clinicians experienced in the acute care of newborn infants with respiratory failure who require intubation.</p><p>&nbsp;</p><p>Rapid and substantial increases in blood oxygenation and improved lung compliance often follow Infasurf instillation. Close clinical monitoring and surveillance following administration may be needed to adjust oxygen therapy and ventilator pressures appropriately.</p><p>&nbsp;</p><p><strong>Dosage </strong></p><p>Each dose of Infasurf is 3 ml/kg body weight at birth. Infasurf has been administered every 12 hours for a total of up to 3 doses.</p><p>&nbsp;</p><p><strong>Directions for Use </strong></p><p>Infasurf is a suspension which settles during storage. Gentle swirling or agitation of the vial is often necessary for redispersion. Do not shake. Visible flecks in the suspension and foaming at the surface are normal for Infasurf.</p><p>&nbsp;</p><p>Infasurf should be stored at refrigerated temperature 2&deg; to 8&deg;C. The 3 ml vial must be stored upright. Date and time need to be recorded on the carton when Infasurf is removed from the refrigerator. Warming of Infasurf before administration is not necessary.</p><p>&nbsp;</p><p>Unopened, unused vials of Infasurf that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. Infasurf should not be removed from the refrigerator for more than 24 hours. Infasurf should not be returned to the refrigerator more than once.<strong> </strong>Repeated warming to room temperature should be avoided. Each single-use vial should be entered only once and the vial with any unused material should be discarded after the initial entry.</p><p>&nbsp;</p><p>Infasurf does not require reconstitution. Do not dilute or sonicate.</p><p>&nbsp;</p><p><strong>Dosing procedures </strong></p><p><em>General </em></p><p>Infasurf should only be administered intratracheally through an endotracheal tube. The dose of Infasurf is 3 ml/kg birth weight. The dose is drawn into a syringe from the single-use vial using a 20-gauge or larger needle with care taken to avoid excessive foaming. Administration is made by instillation of the Infasurf suspension into the endotracheal tube.</p><p>&nbsp;</p><p><strong>Administration for treatment of RDS </strong></p><p><em>When used to treat RDS, Infasurf may be administered using either of the following 2 methods: </em></p><ul><li>Colfosceril palmitate active control trials: initial and repeat dosing</li></ul><p>In the Infasurf vs. colfosceril palmitate trials, Infasurf was administered intratracheally through a side-port adapter into the endotracheal tube. Two attendants, one to instill the Infasurf, the other to monitor the patient and assist in positioning, facilitated the dosing.</p><p>&nbsp;</p><p>The dose (3 ml/kg) was administered in two aliquots of 1.5 ml/kg each. After each aliquot was instilled, the infant was positioned with either the right or the left side dependent. Administration was made while ventilation was continued over 20-30 breaths for each aliquot, with small bursts timed only during the inspiratory cycles. A pause followed by evaluation of the respiratory status and repositioning separated the two aliquots. Repeat doses of 3 ml/kg of birth weight, up to a total of 3 doses 12 hours apart, were given if the patient was still intubated.</p><p>&nbsp;</p><ul><li>Beractant active control trials: initial and repeat dosing</li></ul><p>In the Infasurf vs. beractant trials, Infasurf was administered through a 5 French feeding catheter inserted into the endotracheal tube. The total dose was instilled in four equal aliquots with the catheter removed between each of the instillations and mechanical ventilation resumed for 0.5 to 2 minutes. Each of the aliquots was administered with the patient in one of four different positions (prone, supine, right, and left lateral) to facilitate even distribution of the surfactant.</p><p>&nbsp;</p><p>Repeat doses were administered as early as 6 hours after the previous dose for a total of up to 4 doses if the infant was still intubated and required at least 30% inspired oxygen to maintain a PaO<sup>2</sup> &le; 80 torr.</p><p>&nbsp;</p><p><em>Administration for prophylaxis of RDS at birth </em></p><p>Dosing procedures are described under Administration for Treatment of RDS. The amount of a prophylaxis dose of Infasurf should be based on the infant&#39;s birth weight. Administration of Infasurf for prophylaxis should be given as soon as possible after birth. Usually the immediate care and stabilization of the premature infant born with hypoxemia and/or bradycardia should precede Infasurf prophylaxis.</p><p>&nbsp;</p><p><strong>Dosing precautions </strong></p><p>During administration of Infasurf liquid suspension into the airway, infants often experience bradycardia, reflux of Infasurf into the endotracheal tube, airway obstruction, cyanosis, dislodgement of the endotracheal tube, or hypoventilation. If any of these events occur, the administration should be interrupted and the infant&#39;s condition should be stabilized using appropriate interventions before the administration of Infasurf is resumed. Endotracheal suctioning or reintubation is sometimes needed when there are signs of airway obstruction during the administration of the surfactant.</p><p>&nbsp;</p><p><strong>If you use more </strong><strong>Infasurf</strong><strong> </strong><strong>than you should</strong></p><p>There have been no reports of overdosage with Infasurf. While there are no known adverse effects of excess lung surfactant, overdosage would result in overloading the lungs with an isotonic solution. Ventilation should be supported until clearance of the liquid is accomplished.</p><p><strong>&nbsp;</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The most common adverse reactions associated with Infasurf dosing procedures in the controlled trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), reflux of surfactant into the endotracheal tube (21%), requirement for manual ventilation (16%), and reintubation (3%). These events were generally transient and not associated with serious complications or death. The incidence of common complications of prematurity and RDS in the four controlled Infasurf trials are presented in Table 1. Prophylaxis and treatment study results for each surfactant are combined.</p><p>&nbsp;</p><p><strong>Table 1 - Common complications of prematurity and RDS in controlled trials</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Complication </strong></p></td><td style="vertical-align:top"><p><strong>Infasurf (N=1001) % </strong></p></td><td style="vertical-align:top"><p><strong>Colfosceril palmitate (N=978) % </strong></p></td><td style="vertical-align:top"><p><strong>Infasurf (N=553) % </strong></p></td><td style="vertical-align:top"><p><strong>Beractant (N=566) % </strong></p></td></tr><tr><td style="vertical-align:top"><p>Apnea</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>76</p></td><td style="vertical-align:top"><p>76</p></td></tr><tr><td style="vertical-align:top"><p>Patent ductus arteriosus</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>45 &nbsp;</p></td><td style="vertical-align:top"><p>48</p></td></tr><tr><td style="vertical-align:top"><p>Intracranial hemorrhage</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>Severe Intracranial hemorrhage <sup>a</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>IVH and PVL <sup>b </sup></p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>27</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary air leaks</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary interstitial emphysema</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary hemorrhage</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Necrotizing enterocolitis</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>18</p></td></tr></tbody></table><p>a Grade III and IV by the method of Papile.</p><p>b Patients with both intraventricular hemorrhage and periventricular leukomalacia.</p><p>&nbsp;</p><p><em>Follow-up Evaluations</em></p><p>Two-year follow-up data of neurodevelopmental outcomes in 415 infants enrolled in 5 centers that participated in the infasurf vs. colfosceril palmitate controlled trials demonstrated significant developmental delays in equal percentages of Infasurf and colfosceril palmitate patients.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package in order to protect from light.</p><p>The 3 ml vial must be stored upright.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is calfactant.</p><p>&nbsp;</p><p>Each ml of Infasurf 35 mg/ml Intratracheal Suspension contains 35 mg phospholipids and 0.7 mg protein.</p><p>&nbsp;</p><p>The other ingredients are 0.9% sodium chloride for irrigation and sterile water for irrigation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Infasurf 35 mg/ml Intratracheal Suspension is an off-white suspension in 5 ml nominal capacity type I flint glass serum vials, closed with grey ultraclean blowback bromobutyl stoppers. 

Pack sizes: 1 Vial (3 ml and/or 6 ml). 

Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder </strong></p><p>Jazeera Pharmaceutical Industries</p><p>Al-Kharj Road</p><p>P.O. Box 106229</p><p>Riyadh 11666, Saudi Arabia</p><p>Tel: + (966-11) 8107023, + (966-11) 2142472</p><p>Fax: + (966-11) 2078170</p><p>e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Manufacturer and Under licensed from</strong></p><p>ONY Biotech Inc.</p><p>1576 Sweet Home Road</p><p>Amherst, New York, 14228 USA</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 08/2023; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إنفاسيرف هو عبارة عن خافض للتوتر السطحي للرئة معقم، وغير مسببة للحمى مخصص للتقطير داخل القصبة الهوائية فقط. وهو عبارة عن مستخلص من خافض للتوتر السطحي طبيعي من رئتي العجول والذي يتضمن الدهون الفوسفاتية، الدهون المحايدة، والبروتينات المرتبطة بخافض التوتر السطحي الطارد للماء ب وج (البروتين المرتبط بخافض التوتر السطحي ب والبروتين المرتبط بخافض التوتر السطحي ج).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوصف إنفاسيرف للوقاية من متلازمة ضيق التنفس عند أطفال الخدج المعرضين لخطر كبير للإصابة بمتلازمة ضيق التنفس ولعلاج (&quot;الإنقاذ&quot;) أطفال الخدج الذين أصيبوا بمتلازمة ضيق التنفس. يقلل إنفاسيرف حدوث متلازمة ضيق التنفس، الوفيات الناتجة عنها، وتسرب الهواء المصاحب لها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلاج الوقائي </strong></p><p dir="RTL">يوصى بالعلاج الوقائي عند الولادة باستخدام إنفاسيرف لأطفال الخدج الأصغر من 29 أسبوعًا من عمر الحمل المعرضين لخطر كبير للإصابة بمتلازمة ضيق التنفس. يجب إعطاء العلاج الوقائي إنفاسيرف في أسرع وقت ممكن، ويفضل أن يكون ذلك خلال 30 دقيقة بعد الولادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلاج </strong></p><p dir="RTL">يوصى بالعلاج بإنفاسيرف للرضع الذين تقل أعمارهم عن أو تساوي 72 ساعة المصابين بمتلازمة ضيق التنفس (تؤكدها النتائج البحثية والإشعاعية) والذين يلزمهم تنبيب القصبة الهوائية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم إنفاسيرف</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لكالفاكتانت أو لأي من المواد الأخرى المستخدمة في مكونات هذا الدواء (المذكورة في القسم 6).</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL"><em>التحذيرات </em></p><p dir="RTL">إنفاسيرف مخصص للاستخدام داخل القصبة الهوائية فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غالبًا ما يؤدي استخدام المواد الخافضة للتوتر السطحي الخارجية، بما في ذلك إنفاسيرف، إلى تحسين عمليات الأكسجة وامتثال الرئة بسرعة. بعد إعطاء إنفاسيرف، يجب مراقبة المرضى بعناية بحيث يمكن تعديل العلاج بالأكسجين ودعم التنفس الصناعي استجابة للتغيرات في حالة الجهاز التنفسي. علاج إنفاسيرف ليس بديلاً عن العناية المركزة لحديثي الولادة. تتطلب الرعاية المثلى لأطفال الخدج المعرضين لخطر الإصابة بمتلازمة ضيق التنفس والمصابين بها الذين يحتاجون إلى تتبيب القصبة الهوائية وحدة رعاية حادة منظمة مجهزة بموظفين وأجهزة وبخبرة في التنبيب، إدارة جهاز التنفس الصناعي والرعاية العامة لهؤلاء المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حدثت نوبات عابرة من ارتداد إنفاسيرف إلى أنبوب القصبة الهوائية، الزرقة، بطء القلب أو انسداد مجرى الهواء في أثناء إجراءات الجرعات. تتطلب هذه الأحداث وقف إعطاء إنفاسيرف واتخاذ الإجراءات المناسبة لتخفيف الحالة. بعد استقرار المريض، يمكن أن تتابع الجرعات المراقبة المناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الاحتياطات </em></p><p dir="RTL">عند إعطاء الجرعات المتكررة على فترات ثابتة مدتها 12 ساعة في تجارب إنفاسيرف مقابل كولفوسيريل بالميتات، لوحظت نوبات عابرة من الزرقة، بطء القلب، ارتجاع الفاعل بالسطح إلى أنبوب القصبة الهوائية، وانسداد مجرى الهواء بشكل متكرر بين الرضع في المجموعة المعالجة بإنفاسيرف. لوحظت نسبة متزايدة من المرضى الذين يعانون من كل من النزف داخل البطيني وتلين ابيضاض الدم حول البطيني في الرضع المعالجين بالعامل في تجارب إنفاسيرف-كولفوسيريل بالميتات المتحكم بها. لم تقترن هذه الملاحظات بزيادة معدل الوفيات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا توجد بيانات متاحة عن استخدام إنفاسيرف بالاقتران مع العلاجات التجريبية لمتلازمة ضيق التنفس، على سبيل المثال، التهوية عالية التردد. تقتصر البيانات المستمدة من التجارب المتحكم بها على فعالية إنفاسيرف على جرعات تبلغ حوالي 100 ملغم فوسفوليبيد/كغم من وزن الجسم وما يصل إلى إجمالي 4 جرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>التسرطن، التطفير وضعف الخصوبة </em></p><p dir="RTL">لم يتم إجراء دراسات السرطنة ودراسات التكاثر الحيواني باستخدام إنفاسيرف. كانت دراسة الطفرات المفردة (اختبار أميس) سلبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وإنفاسيرف</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">اطلبي النصيحة من طبيبك أو الصيدلي قبل استخدام هذا الدواء إذا كنتِ حاملاً أو مرضعًا، تعتقدين بأنك حاملاً أو تخططين للحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي إنفاسيرف على الصوديوم</strong></p><p dir="RTL">يحتوي إنفاسيرف على الصوديوم. يحتوي كل مللتر من إنفاسيرف 35 ملغم/مللتر معلق للاستخدام داخل القصبات الهوائية على 3.51 ملغم صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم)&nbsp; لكل مللتر، وبذلك يعتبر &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي<strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">للاستخدام داخل القصبة الهوائية فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يُعطى إنفاسيرف تحت إشراف الأطباء ذوي الخبرة في الرعاية الحادة للرضع حديثي الولادة المصابين بفشل تنفسي والذين يحتاجون إلى التنبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غالبًا ما يتبع تقطير إنفاسيرف الزيادات السريعة والجوهرية في عمليات الأكسجة في الدم وتحسين امتثال الرئة. قد يلزم الملاحظة والمراقبة البحثيتان عن قُرب بعد التقديم وذلك لضبط علاج الأكسجين وضغوط جهاز التنفس الصناعي على النحو المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة </strong></p><p dir="RTL">كل جرعة من إنفاسيرف 3 مللتر/كغم من وزن الجسم عند الولادة. تم إعطاء إنفاسيرف كل 12 ساعة ليصبح المجموع 3 جرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام </strong></p><p dir="RTL">إنفاسيرف هو معلق يترسب عتد تخزينه. غالبًا ما يلزم تدوير أو تحريك الزجاجة بلطف لإعادة توزيعه. لا ترج القنينة. البقع المرئية في المعلق والرغوة على السطح طبيعيان في إنفاسيرف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يحفظ إنفاسيرف عند درجة حرارة مبردة من 2&deg; إلى 8&deg; مئوية. يجب حفظ الزجاجة بحجم 3 مللتر في وضع قائم. يجب تسجيل التاريخ والوقت على العبوة الكرتونية عند إخراج إنفاسيرف من الثلاجة. لا يلزم تدفئة إنفاسيرف قبل إعطائه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعادة زجاجات إنفاسيرف غير المفتوحة وغير المستخدمة والتي تم تدفئتها حتى وصلت إلى درجة حرارة الغرفة إلى التخزين المبرد في غضون 24 ساعة لاستخدامها فيما بعد. يجب ألا يُخرج إنفاسيرف من الثلاجة لمدة تتجاوز 24 ساعة. يجب ألا يُعاد إنفاسيرف إلى الثلاجة أكثر من مرة واحدة. يجب تجنب تكرار التدفئة إلى درجة حرارة الغرفة. يجب الإدخال مرة واحدة لكل قنينة مخصصة للاستخدام مرة واحدة، ويجب التخلص من القنينة التي تحتوي على أي مادة غير مستخدمة بعد الإدخال الأول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يلزم تحضير إنفاسيرف. يجب تجنب تخفيفه أو تعريضه للموجات الصوتية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إجراءات الجرعات </strong></p><p dir="RTL"><em>عامة </em></p><p dir="RTL">يجب أن يُعطى إنفاسيرف داخل القصبة الهوائية فقط من خلال أنبوب مخصص للاستخدام داخل القصبة الهوائية. كل جرعة من إنفاسيرف تكون 3 مللتر/كغم من وزن الجسم عند الولادة. تُسحب الجرعة في حقنة من القنينة المخصصة للاستخدام مرة واحدة باستخدام إبرة قياس 20 أو أكبر مع الحرص على تجنب تشكيل الرغوة المفرطة. يٌقدم عن طريق تقطير معلق إنفاسيرف في أنبوب القصبة الهوائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإعطاء لعلاج متلازمة ضيق التنفس </strong></p><p dir="RTL"><em>عند استخدامه لعلاج متلازمة ضيق التنفس، يمكن إعطاء إنفاسيرف باستخدام أي من الطريقتين التاليتين: </em></p><ul dir="rtl"><li>تجارب التحكم النشط لكولفوسيريل بالميتات: الجرعات الأولية والمكررة</li></ul><p dir="RTL">في تجارب إنفاسيرف مقابل كولفوسيريل بالميتات، تم تقديم إنفاسيرف داخل القصبة الهوائية من خلال محول منفذ جانبي في أنبوب القصبة الهوائية. قام مساعدان بتسهيل إعطاء الجرعات، أحدهما لغرس إنفاسيرف، والآخر لملاحظة المريض والمساعدة في الوضع بدقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم إعطاء الجرعة (3 مللتر/كغم) على قسمين كل منهما 1.5 مللتر/كغم. بعد انتهاء تقطير كل قسم، وُضِع الرضيع إما مع داعم الجانب الأيمن أو الأيسر. تم التقديم مع استمرار التهوية لأكثر من 20-30 نفسًا لكل قسم، مع رشقات صغيرة موقوتة في أثناء دورات الشهيق فقط. تفصل وقفة يتبعها تقييم لحالة الجهاز التنفسي وتغيير الموضع بين القسمين. تم إعطاء جرعات متكررة مقدارها 3 مللتر/كغم من وزن الولادة، بإجمالي 3 جرعات بفارق 12 ساعة، إذا كان المريض لا يزال تحت الأنبوب. &nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><ul dir="rtl"><li>تجارب التحكم النشطة لبيراكتانت: الجرعات الأولية والمكررة</li></ul><p dir="RTL">في تجارب إنفاسيرف مقابل بيراكتانت، تم تقديم إنفاسيرف من خلال قسطرة تغذية فرنسية 5 تم إدخالها في أنبوب القصبة الهوائية. تم تقطير الجرعة الإجمالية في أربعة أقسام متساوية مع إزالة القسطرة بين كل من عمليات التقطير واستئناف التهوية الميكانيكية لمدة&nbsp; نصف دقيقة إلى دقيقتين. تم تقديم كل قسم مع المريض في واحد من أربعة مواضع مختلفة (جانبي، مستلق، يمين، ويسار) لتسهيل التوزيع المتساوي للمادة الخافضة للتوتر السطحي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم تقديم جرعات متكررة في وقت مبكر بعد 6 ساعات من الجرعة السابقة، بعدد كلي يساوي 4 جرعات، إذا كان الرضيع ما يزال خاضعًا للأنبوب ولزمه 30% على الأقل من الأكسجين الملهم للحفاظ على ضغط أكسجين شرياني أقل من أو يساوي 80 تور &quot;وحدة ضغط&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الإعطاء للوقاية من متلازمة ضيق التنفس عند الولادة </em></p><p dir="RTL">يرد وصف إجراءات الجرعات تحت الإعطاء لعلاج متلازمة ضيق التنفس. يجب أن تعتمد كمية الجرعة الوقائية من إنفاسيرف على وزن الطفل عند ولادته. يجب تقديم إنفاسيرف علاجًا وقائيًا في أقرب وقت ممكن بعد الولادة مباشرةً. عادة يجب أن تسبق الرعاية الفورية واستقرار طفل الخدج المولود بنقص تأكسج الدم و/أو بطء القلب العلاج الوقائي بإنفاسيرف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احتياطات الجرعات </strong></p><p dir="RTL">أثناء تقديم المعلق السائل لإنفاسيرف في مجرى الهواء، غالبًا ما يعاني الأطفال من بطء القلب، ارتداد إنفاسيرف في أنبوب القصبة الهوائية، انسداد مجرى الهواء، الزرقة، خلع أنبوب القصبة الهوائية، أو نقص التهوية. في حالة حدوث أي من هذه الأحداث، يجب قطع الإعطاء ويجب العمل على استقرار حالة الرضيع باستخدام التدخلات المناسبة قبل استئناف إعطاء إنفاسيرف. يلزم أحيانًا الشفط أو إعادة تتبيب القصبة الهوائية عند وجود مؤشرات تدل على انسداد مجرى الهواء في أثناء إعطاء خافض التوتر السطحي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت إنفاسيرف أكثر من اللازم</strong></p><p dir="RTL">لم ترد حالات إبلاغ عن جرعة زائدة مع إنفاسيرف. لا توجد آثار ضارة معروفة لزيادة خافض التوتر السطحي للرئة، لكن الجرعة الزائدة قد تؤدي إلى زيادة تحميل الرئتين بمحلول متساوي التوتر. يجب دعم التهوية حتى إتمام التخلص من السائل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، فيُرجى استشارة طبيبك، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كانت التفاعلات الضارة الأكثر شيوعًا المرتبطة بإجراءات جرعات إنفاسيرف في التجارب المتحكم بها هي الزرقة (65%)، انسداد مجرى الهواء (39%)، بطء القلب (34%)، ارتداد خافض التوتر السطحي إلى أنبوب القصبة الهوائية (21%)، متطلبات التهوية اليدوية (16%)، وإعادة التنبيب (3%). كانت هذه الأحداث عابرة بشكل عام ولم تقترن بمضاعفات خطيرة أو الوفاة. يعرض الجدول 1 حدوث المضاعفات الشائعة للأطفال الخدج ومتلازمة ضيق التنفس في تجارب إنفاسيرف الأربعة المتحكم بها. تُجمع نتائج دراسة العلاج الوقائي والعلاج لكل مادة خافضة للتوتر السطحي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجدول 1 - المضاعفات الشائعة للأطفال الخدج ومتلازمة ضيق التنفس في التجارب الخاضعة للتحكم</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المضاعفات </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>إنفاسيرف (العدد=1001) % </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>كولفوسيريل بالميتات (العدد =978) % </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>إنفاسيرف (العدد =553) % </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>بيراكتانت (العدد =566) % </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انقطاع النفس</p></td><td style="vertical-align:top"><p dir="RTL">61</p></td><td style="vertical-align:top"><p dir="RTL">61</p></td><td style="vertical-align:top"><p dir="RTL">76</p></td><td style="vertical-align:top"><p dir="RTL">76</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">القناة الشريانية المفتوحة</p></td><td style="vertical-align:top"><p dir="RTL">47</p></td><td style="vertical-align:top"><p dir="RTL">47</p></td><td style="vertical-align:top"><p dir="RTL">45</p></td><td style="vertical-align:top"><p dir="RTL">48</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نزيف داخل الجمجمة</p></td><td style="vertical-align:top"><p dir="RTL">29</p></td><td style="vertical-align:top"><p dir="RTL">31</p></td><td style="vertical-align:top"><p dir="RTL">36</p></td><td style="vertical-align:top"><p dir="RTL">36</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نزيف حاد داخل الجمجمة <sup>أ</sup></p></td><td style="vertical-align:top"><p dir="RTL">12</p></td><td style="vertical-align:top"><p dir="RTL">10</p></td><td style="vertical-align:top"><p dir="RTL">9</p></td><td style="vertical-align:top"><p dir="RTL">7</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نزيف داخل البطين وتلين ابيضاض الدم حول البطين <sup>ب</sup></p></td><td style="vertical-align:top"><p dir="RTL">7</p></td><td style="vertical-align:top"><p dir="RTL">3</p></td><td style="vertical-align:top"><p dir="RTL">5</p></td><td style="vertical-align:top"><p dir="RTL">5</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الإنتان</p></td><td style="vertical-align:top"><p dir="RTL">20</p></td><td style="vertical-align:top"><p dir="RTL">22</p></td><td style="vertical-align:top"><p dir="RTL">28</p></td><td style="vertical-align:top"><p dir="RTL">27</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تسرب الهواء الرئوي</p></td><td style="vertical-align:top"><p dir="RTL">12</p></td><td style="vertical-align:top"><p dir="RTL">22</p></td><td style="vertical-align:top"><p dir="RTL">15</p></td><td style="vertical-align:top"><p dir="RTL">15</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انتفاخ الرئة الخلالي الرئوي</p></td><td style="vertical-align:top"><p dir="RTL">7</p></td><td style="vertical-align:top"><p dir="RTL">17</p></td><td style="vertical-align:top"><p dir="RTL">10</p></td><td style="vertical-align:top"><p dir="RTL">10</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نزيف رئوي</p></td><td style="vertical-align:top"><p dir="RTL">7</p></td><td style="vertical-align:top"><p dir="RTL">7</p></td><td style="vertical-align:top"><p dir="RTL">7</p></td><td style="vertical-align:top"><p dir="RTL">6</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الأمعاء</p></td><td style="vertical-align:top"><p dir="RTL">5</p></td><td style="vertical-align:top"><p dir="RTL">5</p></td><td style="vertical-align:top"><p dir="RTL">17</p></td><td style="vertical-align:top"><p dir="RTL">18</p></td></tr></tbody></table><p dir="RTL">أ الدرجة 3 و4 بطريقة بابيلي.</p><p dir="RTL">ب المرضى الذين يعانون من كل من نزيف داخل البطين وتلين ابيضاض الدم حول البطين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>تقييمات المتابعة</em></p><p dir="RTL">أظهرت بيانات المتابعة المستمرة لعامين لنتائج النمو العصبي في 415 رضيعًا مسجلين في 5 مراكز شاركت في التجارب المتحكم بها لإنفاسيرف مقابل كولفوسيريل بالميتات، تأخير كبير في النمو بنسب متساوية من مرضى إنفاسيرف وكولفوسيريل بالميتات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى إخبار طبيبك، مقدم الرعاية الصحية أو الصيدلي في حال أصبحت أي من الآثار الجانبية خطيرة أو في حال ظهور أية آثار جانبية لم تذكر في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ داخل الثلاجة (2-8&deg; مئوية).</p><p dir="RTL">يحفظ داخل العبوة الأصلیة للحمایة من الضوء.</p><p dir="RTL">يجب حفظ الزجاجة بحجم 3 مللتر في وضع قائم. &nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات تساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي كالفاكتانت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل مللتر من إنفاسيرف 35 ملغم/مللتر معلق للاستخدام داخل القصبات الهوائية على 35 ملغم فوسفوليبيد و0.7 ملغم بروتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي 0.9% كلوريد الصوديوم معد للغسل وماء معقم معد للغسل.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل </strong><strong>إنفاسيرف ووصفه ومحتويات العبوة</strong><strong> </strong></p><p dir="RTL">إنفاسيرف 35 ملغم/مللتر معلق للاستخدام داخل القصبات الهوائية هو معلق أبيض مصفر في زجاجات مصل من الزجاج الصوّانيّ من النوع رقم واحد بسعة نظرية تبلغ 5 مللتر، مغلق بسدادات بروموبوتيل رمادية ذات ارتداد فائقة النظافة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات: زجاجة واحدة (3 مللتر و/أو 6 مللتر).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة وبترخيص من</strong></p><p dir="RTL">شركة أوني بيوتيك المحدودة</p><p dir="RTL">1576 طريق سويت هوم</p><p dir="RTL">امهيرست، نيويورك، 14228 الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، أو الصيدلي، أو الممرض إذا عانيت أي آثار جانبية. وذلك يشمل أي آثار جانبية لم ترد في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&nbsp;</strong></p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 08/2023؛ رقم النسخة SA1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Infasurf 35 mg/ml Intratracheal Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Infasurf 35 mg/ml Intratracheal Instillation, suspension is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation only.  It is an extract of natural surfactant from calf lungs which includes phospholipids, neutral lipids, and hydrophobic surfactant-associated proteins B and C (SP-B and SP-C).  It contains no preservatives.  

Infasurf is an off-white suspension of calfactant in 0.9% aqueous sodium chloride solution.  It has a pH of 5.0-6.2 (target 5.7).  Each ml of Infasurf 35 mg/ml Intratracheal Suspension contains 35 mg phospholipids and 0.7 mg protein. 

Excipients with known effect: Sodium. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Intratracheal suspension.

Off-white suspension.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Infasurf is indicated for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment (&ldquo;rescue&rdquo;) of premature infants who develop RDS. Infasurf decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS.</p><p>&nbsp;</p><p><strong>Prophylaxis </strong></p><p>Prophylaxis therapy at birth with Infasurf is indicated for premature infants &lt; 29 weeks of gestational age at significant risk for RDS. Infasurf prophylaxis should be administered as soon as possible, preferably within 30 minutes after birth.</p><p>&nbsp;</p><p><strong>Treatment </strong></p><p>Infasurf therapy is indicated for infants &le; 72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FOR INTRATRACHEAL ADMINISTRATION ONLY.</p><p>&nbsp;</p><p>Infasurf should be administered under the supervision of clinicians experienced in the acute care of new-born infants with respiratory failure who require intubation.</p><p>&nbsp;</p><p>Rapid and substantial increases in blood oxygenation and improved lung compliance often follow Infasurf instillation. Close clinical monitoring and surveillance following administration may be needed to adjust oxygen therapy and ventilator pressures appropriately.</p><p>&nbsp;</p><p><strong>Dosage </strong></p><p>Each dose of Infasurf is 3 ml/kg body weight at birth. Infasurf has been administered every 12 hours for a total of up to 3 doses.</p><p>&nbsp;</p><p><strong>Directions for Use </strong></p><p>Infasurf is a suspension which settles during storage. Gentle swirling or agitation of the vial is often necessary for redispersion. DO NOT SHAKE. Visible flecks in the suspension and foaming at the surface are normal for Infasurf.</p><p>&nbsp;</p><p>Infasurf should be stored at refrigerated temperature 2&deg; to 8&deg;C. The 3 ml vial must be stored upright. Date and time need to be recorded on the carton when Infasurf is removed from the refrigerator. Warming of Infasurf before administration is not necessary.</p><p>&nbsp;</p><p>Unopened, unused vials of Infasurf that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. Infasurf should not be removed from the refrigerator for more than 24 hours. Infasurf should not be returned to the refrigerator more than once.<strong> </strong>Repeated warming to room temperature should be avoided. Each single-use vial should be entered only once and the vial with any unused material should be discarded after the initial entry.</p><p>&nbsp;</p><p><strong>Infasurf does not require reconstitution. Do not dilute or sonicate. </strong></p><p>&nbsp;</p><p><strong>Dosing procedures </strong></p><p><em>General </em></p><p>Infasurf should only be administered intratracheally through an endotracheal tube. The dose of Infasurf is 3 ml/kg birth weight. The dose is drawn into a syringe from the single-use vial using a 20-gauge or larger needle with care taken to avoid excessive foaming. Administration is made by instillation of the Infasurf suspension into the endotracheal tube.</p><p>&nbsp;</p><p><strong>Administration for treatment of RDS </strong></p><p><em>When used to treat RDS, Infasurf may be administered using either of the following 2 methods: </em></p><ul><li>Colfosceril palmitate active control trials: initial and repeat dosing</li></ul><p>In the Infasurf vs. colfosceril palmitate trials, Infasurf was administered intratracheally through a side-port adapter into the endotracheal tube. Two attendants, one to instill the Infasurf, the other to monitor the patient and assist in positioning, facilitated the dosing.</p><p>&nbsp;</p><p>The dose (3 ml/kg) was administered in two aliquots of 1.5 ml/kg each. After each aliquot was instilled, the infant was positioned with either the right or the left side dependent. Administration was made while ventilation was continued over 20-30 breaths for each aliquot, with small bursts timed only during the inspiratory cycles. A pause followed by evaluation of the respiratory status and repositioning separated the two aliquots. Repeat doses of 3 ml/kg of birth weight, up to a total of 3 doses 12 hours apart, were given if the patient was still intubated.</p><p>&nbsp;</p><ul><li>Beractant active control trials: initial and repeat dosing</li></ul><p>In the Infasurf vs. beractant trials, Infasurf was administered through a 5 French feeding catheter inserted into the endotracheal tube. The total dose was instilled in four equal aliquots with the catheter removed between each of the instillations and mechanical ventilation resumed for 0.5 to 2 minutes. Each of the aliquots was administered with the patient in one of four different positions (prone, supine, right, and left lateral) to facilitate even distribution of the surfactant.</p><p>&nbsp;</p><p>Repeat doses were administered as early as 6 hours after the previous dose for a total of up to 4 doses if the infant was still intubated and required at least 30% inspired oxygen to maintain a PaO2 &le; 80 torr.</p><p>&nbsp;</p><p><em>Administration for prophylaxis of RDS at birth </em></p><p>Dosing procedures are described under Administration for Treatment of RDS. The amount of a prophylaxis dose of Infasurf should be based on the infant&#39;s birth weight. Administration of Infasurf for prophylaxis should be given as soon as possible after birth. Usually the immediate care and stabilization of the premature infant born with hypoxemia and/or bradycardia should precede Infasurf prophylaxis.</p><p>&nbsp;</p><p><strong>Dosing precautions </strong></p><p>During administration of Infasurf liquid suspension into the airway, infants often experience bradycardia, reflux of Infasurf into the endotracheal tube, airway obstruction, cyanosis, dislodgement of the endotracheal tube, or hypoventilation. If any of these events occur, the administration should be interrupted and the infant&#39;s condition should be stabilized using appropriate interventions before the administration of Infasurf is resumed. Endotracheal suctioning or reintubation is sometimes needed when there are signs of airway obstruction during the administration of the surfactant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Not applicable.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Warnings </em></p><p>Infasurf is intended for intratracheal use only.</p><p>&nbsp;</p><p>The administration of exogenous surfactants, including Infasurf, often rapidly improves oxygenation and lung compliance. Following administration of Infasurf, patients should be carefully monitored so that oxygen therapy and ventilatory support can be modified in response to changes in respiratory status. Infasurf therapy is not a substitute for neonatal intensive care. Optimal care of premature infants at risk for RDS and newborn infants with RDS who need endotracheal intubation requires an acute care unit organized, staffed, equipped, and experienced with intubation, ventilator management, and general care of these patients.</p><p>&nbsp;</p><p>Transient episodes of reflux of Infasurf into the endotracheal tube, cyanosis, bradycardia, or airway obstruction have occurred during the dosing procedures. These events require stopping Infasurf administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing can proceed with appropriate monitoring.</p><p>&nbsp;</p><p><em>Precautions </em></p><p>When repeat dosing was given at fixed 12-hour intervals in the Infasurf vs. colfosceril palmitate trials, transient episodes of cyanosis, bradycardia, reflux of surfactant into the endotracheal tube, and airway obstruction were observed more frequently among infants in the Infasurf-treated group.</p><p>&nbsp;</p><p>An increased proportion of patients with both intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) was observed in Infasurf-treated infants in the Infasurf-colfosceril palmitate-controlled trials. These observations were not associated with increased mortality.</p><p>&nbsp;</p><p>No data are available on the use of Infasurf in conjunction with experimental therapies of RDS, e.g., high-frequency ventilation. Data from controlled trials on the efficacy of Infasurf are limited to doses of approximately 100 mg phospholipid/kg body weight and up to a total of 4 doses.</p><p>&nbsp;</p><p><strong>Infasurf</strong><strong> contains sodium</strong></p><p>Infasurf contains sodium. Each ml of Infasurf 35 mg/ml Intratracheal Suspension contains 3.51 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions associated with Infasurf dosing procedures in the controlled trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), reflux of surfactant into the endotracheal tube (21%), requirement for manual ventilation (16%), and reintubation (3%). These events were generally transient and not associated with serious complications or death. The incidence of common complications of prematurity and RDS in the four controlled Infasurf trials are presented in Table 1. Prophylaxis and treatment study results for each surfactant are combined.</p><p>&nbsp;</p><p><strong>Table 1 - Common complications of prematurity and RDS in controlled trials</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Complication </strong></p></td><td style="vertical-align:top"><p><strong>Infasurf (N=1001) %</strong></p></td><td style="vertical-align:top"><p><strong>Colfosceril palmitate (N=978) %</strong></p></td><td style="vertical-align:top"><p><strong>Infasurf (N=553) %</strong></p></td><td style="vertical-align:top"><p><strong>Beractant (N=566) %</strong></p></td></tr><tr><td style="vertical-align:top"><p>Apnea</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>76</p></td><td style="vertical-align:top"><p>76</p></td></tr><tr><td style="vertical-align:top"><p>Patent ductus arteriosus</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>48</p></td></tr><tr><td style="vertical-align:top"><p>Intracranial hemorrhage</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>Severe Intracranial hemorrhage <sup>a</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>IVH and PVL <sup>b </sup></p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>27</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary air leaks</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary interstitial emphysema</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary hemorrhage</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Necrotizing enterocolitis</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>18</p></td></tr></tbody></table><p>a Grade III and IV by the method of Papile.</p><p>b Patients with both intraventricular hemorrhage and periventricular leukomalacia.</p><p>&nbsp;</p><p><em>Follow-up Evaluations</em></p><p>Two-year follow-up data of neurodevelopmental outcomes in 415 infants enrolled in 5 centers that participated in the Infasurf vs. colfosceril palmitate controlled trials demonstrated significant developmental delays in equal percentages of Infasurf and colfosceril palmitate patients.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions &lt;via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no reports of overdosage with Infasurf. While there are no known adverse effects of excess lung surfactant, overdosage would result in overloading the lungs with an isotonic solution. Ventilation should be supported until clearance of the liquid is accomplished.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Endogenous lung surfactant is essential for effective ventilation because it modifies alveolar surface tension thereby stabilizing the alveoli. Lung surfactant deficiency is the cause of Respiratory Distress Syndrome (RDS) in premature infants. Infasurf restores surface activity to the lungs of these infants.</p><p>&nbsp;</p><p><strong>Activity</strong>: Infasurf adsorbs rapidly to the surface of the air:liquid interface and modifies surface tension similarly to natural lung surfactant. A minimum surface tension of &le;3 mN/m is produced <em>in vitro</em> by Infasurf as measured on a pulsating bubble surfactometer.</p><p>&nbsp;</p><p><em>Ex vivo</em>, Infasurf restores the pressure volume mechanics and compliance of surfactant-deficient rat lungs. <em>In vivo</em>, Infasurf improves lung compliance, respiratory gas exchange, and survival in preterm lambs with profound surfactant deficiency.</p><p>&nbsp;</p><p><strong>Animal Metabolism</strong>: Infasurf is administered directly to the lung lumen surface, its site of action. No human studies of absorption, biotransformation, or excretion of Infasurf have been performed. The administration of Infasurf with radiolabeled phospholipids into the lungs of adult rabbits results in the persistence of 50% of radioactivity in the lung alveolar lining and 25% of radioactivity in the lung tissue 24 hours later. Less than 5% of the radioactivity is found in other organs. In premature lambs with lethal surfactant deficiency, less than 30% of instilled Infasurf is present in the lung lining after 24 hours.</p><p>&nbsp;</p><p><strong>Clinical Studies</strong>: The efficacy of Infasurf was demonstrated in two multiple-dose controlled clinical trials involving approximately 2,000 infants treated with Infasurf (approximately 100 mg phospholipid/kg) or colfosceril palmitate. In addition, two controlled trials of Infasurf versus beractant, and four uncontrolled trials were conducted that involved approximately 15,500 patients treated with Infasurf.</p><p>&nbsp;</p><p><strong>Infasurf </strong><strong>versus colfosceril palmitate</strong><strong> </strong></p><p><em>Treatment Trial </em></p><p>A total of 1,126 infants &le;72 hours of age with RDS who required endotracheal intubation and had an a/A PO2 &lt; 0.22 were enrolled into a multiple-dose, randomized, double-blind treatment trial comparing Infasurf (3mL/kg) and colfosceril palmitate (5 ml/kg). Patients were given an initial dose and one repeat dose 12 hours later if intubation was still required. The dose was instilled in two aliquots through a side port adapter into the proximal end of the endotracheal tube. Each aliquot was given in small bursts over 20-30 inspiratory cycles. After each aliquot was instilled, the infant was positioned with either the right or the left side dependent. Results for efficacy parameters evaluated at 28 days or to discharge for all treated patients from this treatment trial are shown in Table 2.</p><p>&nbsp;</p><p><strong>Table 2 - </strong><strong>Infasurf </strong><strong>vs colfosceril palmitate Treatment Trial</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;Efficacy Parameter </strong></p></td><td style="vertical-align:top"><p><strong>Infasurf </strong><strong>(N=570) % </strong></p></td><td style="vertical-align:top"><p><strong>Colfosceril palmitate </strong><strong>(N=556) % </strong></p></td><td style="vertical-align:top"><p><strong>p-Value </strong></p></td></tr><tr><td style="vertical-align:top"><p>Incidence of air leaks <sup>a </sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Death due to RDS</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0.95</p></td></tr><tr><td style="vertical-align:top"><p>Any death to 28 days</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.21</p></td></tr><tr><td style="vertical-align:top"><p>Any death before discharge</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p>BPD <sup>b</sup></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0.41</p></td></tr><tr><td style="vertical-align:top"><p>Crossover to other surfactant <sup>c </sup></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1</p></td></tr></tbody></table><p>a Pneumothorax and/or pulmonary interstitial emphysema.</p><p>b BPD is bronchopulmonary dysplasia, diagnosed by positive X-ray and oxygen dependence at 28 days.</p><p>c Protocol permitted use of comparator surfactant in patients who failed to respond to therapy with the initial randomized surfactant if the infant was &lt; 96 hours of age, had received a full course of the randomized surfactant, and had an a/A PO2 ratio &lt; 0.10</p><p>&nbsp;</p><p><em>Prophylaxis Trial </em></p><p>A total of 853 infants &lt;29 weeks gestation were enrolled into a multiple-dose, randomized, double-blind prophylaxis trial comparing Infasurf (3 ml/kg) and colfosceril palmitate (5 ml/kg). The initial dose was administered within 30 minutes of birth. Repeat doses were administered at 12 and 24 hours if the patient remained intubated. Each dose was administered divided in 2 equal aliquots, and given through a side port adapter into the proximal end of the endotracheal tube. Each aliquot was given in small bursts over 20-30 inspiratory cycles. After each aliquot was instilled, the infant was positioned with either the right or the left side dependent. Results for efficacy parameters evaluated to day 28 or to discharge for all treated patients from this prophylaxis trial are shown in Table 3.</p><p>&nbsp;</p><p><strong>Table 3 -Infasurf vs colfosceril palmitate Prophylaxis Trial</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Infasurf </strong><strong>(N=431) %</strong></p></td><td style="vertical-align:top"><p><strong>Colfosceril palmitate </strong><strong>(N=422) %</strong></p></td><td style="vertical-align:top"><p><strong>p-Value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Incidence of RDS</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>47</p></td><td><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Incidence of air leaks <sup>a </sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0.01</p></td></tr><tr><td style="vertical-align:top"><p>Death due to RDS</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>5</p></td><td><p>&le;0.01</p></td></tr><tr><td style="vertical-align:top"><p>Any death to 28 days</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.10</p></td></tr><tr><td style="vertical-align:top"><p>Any death before discharge</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>0.56</p></td></tr><tr><td style="vertical-align:top"><p>BPD <sup>b</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>0.60</p></td></tr><tr><td style="vertical-align:top"><p>Crossover to other surfactant <sup>c</sup></p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td></tr></tbody></table><p>a Pneumothorax and/or pulmonary interstitial emphysema.</p><p>b BPD is bronchopulmonary dysplasia, diagnosed by positive X-ray and oxygen dependence at 28 days.</p><p>c Protocol permitted use of comparator surfactant in patients who failed to respond to therapy with the initial randomized surfactant if the infant was &lt; 72 hours of age, had received a full course of the randomized surfactant, and an a/A PO<sub>2</sub> ratio was &lt; 0.10</p><p>&nbsp;</p><p><strong>Infasurf </strong><strong>versus beractant</strong></p><p><em>Treatment Trial </em></p><p>A total of 662 infants with RDS who required endotracheal intubation and had an a/A PO2 &lt;0.22 were enrolled into a multiple-dose, randomized, double-blind treatment trial comparing Infasurf (4 ml/kg of a formulation that contained 25 mg of phospholipids/mL rather than the 35 mg/ml in the marketed formulation) and beractant (4 ml/kg). Repeat doses were allowed &ge;6 hours following the previous treatment (for up to three doses before 96 hours of age) if the patient required &ge;30% oxygen. The surfactant was given through a 5 French feeding catheter inserted into the endotracheal tube. The total dose was instilled in four equal aliquots with the catheter removed between each of the instillations and mechanical ventilation resumed for 0.5 to 2 minutes. Each of the aliquots was administered with the patient in one of four different positions (prone, supine, right, and left lateral) to facilitate even distribution of the surfactant. Results for the major efficacy parameters evaluated at 28 days or to discharge (incidence of air leaks, death due to respiratory causes or to any cause, BPD, or treatment failure) for all treated patients from this treatment trial were not significantly different between Infasurf and beractant.</p><p>&nbsp;</p><p><em>Prophylaxis Trial </em></p><p>A total of 457 infants &le;30 weeks gestation and &lt;1251 grams birth weight were enrolled into a multiple-dose, randomized, double-blind trial comparing Infasurf (4 ml/kg of a formulation that contained 25 mg of phospholipids/mL rather than the 35 mg/mL in the marketed formulation) and beractant (4 ml/kg). The initial dose was administered within 15 minutes of birth and repeat doses were allowed &ge;6 hours following the previous treatment (for up to three doses before 96 hours of age) if the patient required &ge;30% oxygen. The surfactant was given through a 5 French feeding catheter inserted into the endotracheal tube. The total dose was instilled in four equal aliquots with the catheter removed between each of the instillations and mechanical ventilation resumed for 0.5 to 2 minutes. Each of the aliquots was administered with the patient in one of four different positions (prone, supine, right, and left lateral).</p><p>&nbsp;</p><p>Results for efficacy endpoints evaluated at 28 days or to discharge for all treated patients from this prophylaxis trial showed an increase in mortality from any cause at 28 days (p=0.03) and in death due to respiratory causes (p=0.005) in Infasurf-treated infants. For evaluable patients (patients who met the protocol-defined entry criteria), mortality from any cause and mortality due to respiratory causes were also higher in the Infasurf group (p = 0.07 and 0.03, respectively). However, these observations have not been replicated in other adequate and well-controlled trials and their relevance to the intended population is unknown. All other efficacy outcomes (incidence of RDS, air leaks, BPD, and treatment failure) were not significantly different between Infasurf and beractant when analyzed for all treated patients and for evaluable patients.</p><p>&nbsp;</p><p><strong>Acute Clinical Effects: </strong>As with other surfactants, marked improvements in oxygenation and lung compliance may occur shortly after the administration of Infasurf. All controlled clinical trials with Infasurf demonstrated significant improvements in fraction of inspired oxygen (FiO<sub>2</sub>) and mean airway pressure (MAP) during the first 24 to 48 hours following initiation of Infasurf therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Infasurf is administered directly to the lung lumen surface, its site of action. No human studies of absorption, biotransformation, or excretion of Infasurf have been performed. The administration of Infasurf with radiolabeled phospholipids into the lungs of adult rabbits results in the persistence of 50% of radioactivity in the lung alveolar lining and 25% of radioactivity in the lung tissue 24 hours later. Less than 5% of the radioactivity is found in other organs. In premature lambs with lethal surfactant deficiency, less than 30% of instilled Infasurf is present in the lung lining after 24 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis studies and animal reproduction studies have not been performed with Infasurf. A single mutagenicity study (Ames assay) was negative.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; 0.9% Sodium chloride for irrigation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sterile water for irrigation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2-8&deg;C).</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>The 3 ml vial must be stored upright.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml nominal capacity type I flint glass serum vials, closed with grey ultraclean blowback bromobutyl stoppers and aluminum seals.</p><p>&nbsp;</p><p>Pack sizes: 1 Vial (3 ml and/or 6 ml).</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Jazeera Pharmaceutical Industries
	Al-Kharj Road 
	P.O. Box 106229
	Riyadh 11666, Saudi Arabia
	Tel: + (966-11) 8107023, + (966-11) 2142472
	Fax: + (966-11) 2078170
	e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 August 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>